Kiniksa Pharmaceuticals International Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Kiniksa Pharmaceuticals International, plc (KNSA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-43.1914.08183.36-157.92-161.38-161.87-103.23
Depreciation & Amortization1.701.272.322.362.53-1.430.29
Deferred Income Tax8.13-33.79-185.500.014.36-3.16-0.98
Stock Based Compensation30.6927.1525.1225.1720.880.000.00
Change in Working Capital24.814.61-19.570.69-2.62-0.7618.33
Change in Accounts Receivable-20.46-0.95-16.33-3.910.000.000.00
Change in Inventory4.76-9.52-17.92-3.680.000.000.00
Change in Accounts Payable-6.310.356.031.37-4.970.000.00
Change in Other Working Capital3.1411.223.042.630.650.000.00
Other Operating Activities3.1426.9425.152.6320.5815.080.24
Net Cash from Operating Activities25.6913.305.81-126.30-136.53-158.37-81.01
Investing Activities
Capital Expenditures-0.280.130.11-20.420.283.20-5.29
Acquisitions0.030.000.000.000.000.000.00
Purchases of Investments-202.01-29.43-135.86-157.25-23.160.000.00
Sales/Maturities of Investments239.94-29.43-8.06306.30-23.1652.42-233.91
Net Cash from Investing Activities37.67-29.56-8.08128.64-23.4449.21-239.20
Financing Activities
Common Stock Issued17.253.703.425.89443.34166.21350.02
Common Stock Repurchased-4.98-2.21-0.900.000.000.000.00
Other Financing Activities17.25-2.21-0.900.00-1.140.00-3.66
Net Cash from Financing Activities12.271.502.525.89227.0984.11346.74
Summary
Net Change in Cash75.63-14.760.258.2267.11-25.0526.53
Cash at Beginning of Period107.95122.72122.47114.2547.1472.1945.66
Cash at End of Period183.58107.95122.72122.47114.2572.1972.19
Free Cash Flow25.4113.175.79-146.71-136.82-161.57-86.30
Supplemental Disclosures
Income Taxes Paid2.005.6110.691.280.481.720.38